Approved indications: Krazati is indicated for adults with KRAS G12C‑mutated locally advanced or metastatic non-small cell lung cancer after at least one prior systemic therapy, and for adults with KRAS G12C‑mutated locally advanced or metastatic colorectal cancer who have received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, where it is given together with cetuximab.

Off-label and emerging uses: Adagrasib has shown antitumor activity in phase 1/2 studies across other KRAS G12C‑mutated solid tumors (such as pancreatic, biliary tract, appendiceal, small bowel, ovarian, endometrial, and other gastrointestinal cancers), so clinicians may consider it mainly in clinical trials or carefully selected off-label situations, but these uses are not FDA-approved and long-term benefit is still being defined.

Efficacy expectations in NSCLC: In previously treated KRAS G12C‑mutated NSCLC, about 4 in 10 patients have meaningful tumor shrinkage, usually within the first 1–2 months; responses often last many months, with typical progression-free survival around 6–7 months and some patients remaining on treatment for a year or longer, generally outperforming historical second-line chemotherapy and comparable to other KRAS G12C inhibitors.

Efficacy expectations in colorectal cancer: In heavily pretreated KRAS G12C‑mutated colorectal cancer, Krazati plus cetuximab shrinks tumors in roughly one‑third of patients, with disease control in most patients for several months; responses usually appear on early scans and last a median of about 6 months, offering better outcomes than standard late‑line chemotherapy options for this mutation.

Standard adult dosing: For both approved indications, the usual dose is 600 mg of Krazati taken by mouth twice daily (typically three 200‑mg tablets in the morning and three in the evening) as a single agent for KRAS G12C‑mutated NSCLC or together with cetuximab for KRAS G12C‑mutated colorectal cancer, continued until disease progression or unacceptable toxicity.

How to take it: Take doses about 12 hours apart at the same times every day, with or without food, swallowing the tablets whole with water without chewing, crushing, or splitting; if you are also receiving cetuximab, it is given separately by intravenous infusion on a weekly or every‑2‑week schedule as directed by your oncology team.

Dose adjustments and special instructions: If side effects occur, your clinician may temporarily stop Krazati or reduce the dose (first to 400 mg twice daily, then to 600 mg once daily); if you cannot tolerate 600 mg once daily, treatment is usually discontinued. No routine initial dose change is required solely for older age or mild-to-severe kidney or liver impairment, but dosing is individualized based on tolerability and organ function.

Missed doses and vomiting: If you miss a dose, take it as soon as you remember unless more than 4 hours have passed from the usual time, in which case skip that dose and take the next one at the regular time; do not take two doses at once, and if you vomit after taking Krazati, do not take an extra dose—wait and take your next scheduled dose.

Overdose: There is no specific antidote for taking too much Krazati, so suspected overdose should prompt immediate contact with your oncology team, poison control center, or emergency services, where staff can monitor heart rhythm, blood tests, and symptoms and provide supportive care.

Common side effects: Very common effects (often in at least half of patients) include nausea, diarrhea, vomiting, fatigue, and muscle or bone pain; other frequent problems are swelling (edema), shortness of breath, decreased appetite, cough, headache, rash and dry skin (especially when combined with cetuximab), kidney test changes, and abnormal liver tests, which typically begin in the first weeks of therapy and range from mild to moderate but may need anti-nausea or anti-diarrheal medicines and dose changes.

Serious or less common risks needing urgent care: Krazati can cause severe gastrointestinal events (bleeding, obstruction, colitis, or persistent severe diarrhea or vomiting), dangerous heart rhythm changes from QT interval prolongation (fainting, fast or irregular heartbeat), liver injury (yellow skin or eyes, dark urine, right-sided abdominal pain, easy bruising), lung inflammation or interstitial lung disease/pneumonitis (new or worsening cough, fever, or shortness of breath), kidney injury, and serious infections such as pneumonia; any of these warning signs should prompt immediate medical attention.

Warnings and precautions: Treatment requires regular blood tests (liver enzymes, bilirubin, kidney function, blood counts, electrolytes) and ECGs, with extra caution in people who already have liver disease, heart failure, long-QT syndrome, prior serious arrhythmias, significant lung disease, or a history of interstitial lung disease; although pharmacokinetic data do not show major changes in mild-to-severe kidney or liver impairment, clinicians usually monitor such patients more closely and adjust or stop therapy if toxicity develops.

Pregnancy and breastfeeding: There are no adequate data in pregnant people, but animal studies suggest potential fetal harm and Krazati may impair fertility, so use in pregnancy is generally avoided and effective contraception is typically recommended; breastfeeding should not occur during treatment or for at least 1 week after the last dose because of the potential for serious adverse reactions in a nursing infant.

Comparative safety: Compared with traditional cytotoxic chemotherapy, Krazati tends to cause more gastrointestinal upset, liver enzyme elevations, and QT-interval changes but usually less bone-marrow suppression and hair loss; however, side effects are very common and many patients require dose interruptions or reductions, though a substantial proportion can remain on therapy long term with careful monitoring and supportive care.

Safety reporting and updates: Patients should promptly report side effects to their oncology team, and in the United States serious adverse events can also be reported directly to FDA MedWatch (online or via 1-800-FDA-1088), where updated safety information and communications about Krazati are posted.

Prescription and OTC drugs: Krazati is both metabolized by and inhibits several enzymes and transporters (notably CYP3A, CYP2C9, CYP2D6, and P‑glycoprotein), so strong CYP3A inducers such as rifampin, carbamazepine, phenytoin, and St John’s wort can lower its levels and should be avoided, while Krazati can raise blood levels of many other medicines (including some blood thinners, heart rhythm drugs, calcium-channel blockers, opioids, antidepressants, antipsychotics, seizure medicines, and immunosuppressants), sometimes requiring dose adjustments or alternative therapies.

QT‑prolonging agents and heart drugs: Because Krazati itself prolongs the QT interval, combining it with other QT‑prolonging drugs—such as certain antiarrhythmics, macrolide or fluoroquinolone antibiotics, many antipsychotics, and methadone—increases the risk of dangerous arrhythmias, so such combinations are generally avoided or used only with close ECG and electrolyte monitoring.

Acid‑reducing agents, alcohol, and supplements: The prescribing information does not require special restrictions on proton-pump inhibitors or H₂-blockers, but all heartburn medicines, over-the-counter products, and herbal supplements should be reviewed with the oncology team because of possible metabolic or QT effects; limiting alcohol intake is advisable since both alcohol and Krazati can stress the liver.

Food and procedures: Krazati can be taken with or without food, and no specific interactions with imaging contrast agents are known, but patients should tell radiology and anesthesia providers they are taking Krazati so potential QT-, liver-, or kidney-related interactions with sedatives or other peri-procedural drugs can be considered.

Conditions and monitoring: Extra caution is needed in people with existing long-QT syndrome, significant heart failure, uncontrolled electrolyte abnormalities, moderate-to-severe liver disease, prior interstitial lung disease or pneumonitis, or chronic kidney disease; typical monitoring includes baseline and periodic ECGs plus blood tests for liver function, kidney function, and electrolytes (especially potassium and magnesium) throughout treatment.

Q: What is Krazati used to treat?
A: Krazati treats adults whose tumors have a KRAS G12C mutation, including certain cases of locally advanced or metastatic non-small cell lung cancer after at least one prior treatment and colorectal cancer after standard chemotherapy when it is given together with cetuximab.

Q: How long will I need to take Krazati?
A: Most people stay on Krazati as long as it is controlling the cancer and side effects remain manageable, which may be many months for responders, and your oncology team will review scans and labs regularly to decide whether to continue, pause, or stop treatment.

Q: How quickly might Krazati start working?
A: In clinical studies, many patients who respond show some tumor shrinkage on the first or second scan, often within about 1–2 months of starting therapy, though individual responses can be faster or slower.

Q: What should I do if I miss a dose or vomit after taking it?
A: If you miss a dose and remember within 4 hours, you can take it then; if more than 4 hours have passed, skip it and take your next dose at the usual time, and if you vomit after a dose, do not take an extra tablet—just wait for your next scheduled dose and inform your care team if this happens repeatedly.

Q: Can I take Krazati if I have kidney or liver problems?
A: Krazati has been used in patients with a range of kidney and liver function, and no fixed dose change is required just because of mild-to-severe impairment, but your doctor will monitor your blood tests closely and may adjust or stop treatment if liver or kidney tests worsen.

Q: Is Krazati chemotherapy, and will I lose my hair?
A: Krazati is a targeted oral therapy rather than traditional chemotherapy; its most common side effects are gastrointestinal upset, fatigue, rash, and lab test changes, and significant hair loss is not typical, although your overall treatment plan (including other drugs like cetuximab or prior chemotherapies) can also affect hair and other side effects.

Storage: Store Krazati tablets at room temperature (68°F to 77°F / 20°C to 25°C); keep them in the original child-resistant bottle with the desiccant inside, tightly closed, away from moisture, heat, and light, and out of reach of children and pets.

Disposal: Do not flush unused or expired Krazati down the toilet or pour it into drains; instead, use a medicine take-back program or follow your pharmacist’s or local waste authority’s instructions for hazardous medicine disposal, keeping tablets secured until they can be safely discarded.